Cabometyx (cabozantinib) demonstrates real-world survival benefit in advanced renal cell carcinoma

• The study analysed outcomes of adults who were diagnosed with stage III or IV RCC between January 1, 2011 and December 31, 2018, with follow-up lasting until January 31, 2020. A total of 440 patients received cabozantinib treatment, while 1045 received axitinib
• Cabozantinib produced longer survival outcomes than axitinib in patients with advanced RCC that had been previously treated with anti-VEGF agents, according to real-world data presented at the 2021 European Society for Medical Oncology Congress (ESMO)
• Patients treated with cabozantinib had longer median overall survival (OS) than patients treated with axitinib, median OS for cabozantinib treated patients was 11.4 months compared with 9.6 months in axitinib treated patients

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref: RWEMAY2022TNTH